Australia - English - Department of Health (Therapeutic Goods Administration)

getz healthcare pty ltd - 66270 - sclerotherapy dual injection/aspiration catheter - sclerosafe, a peripheral percutaneous catheter intended for short term access to the peripheral venous system for selected intravenous therapies, administration of fluids and blood sampling. specifically, sclerosafe is indicated for obliteration of small up to 5 mm superficial veins for treatment of varicosities.

European Union - English - EMA (European Medicines Agency)

sanofi winthrop industrie - teriflunomide - multiple sclerosis - selective immunosuppressants - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5.1 for important information on the population for which efficacy has been established).

European Union - English - EMA (European Medicines Agency)

biogen netherlands b.v.  - interferon beta-1a - multiple sclerosis - immunostimulants, - avonex is indicated for the treatment of:patients diagnosed with relapsing multiple sclerosis (ms). in clinical trials, this was characterised by two or more acute exacerbations (relapses) in the previous three years without evidence of continuous progression between relapses; avonex slows the progression of disability and decreases the frequency of relapses;patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite ms.avonex should be discontinued in patients who develop progressive ms.

European Union - English - EMA (European Medicines Agency)

bayer ag  - interferon beta-1b - multiple sclerosis - immunostimulants, - betaferon is indicated for the treatment ofpatients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis;patients with relapsing-remitting multiple sclerosis and two or more relapses within the last two years;patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses.

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - interferon beta-1b - multiple sclerosis - immunostimulants, - extavia is indicated for the treatment of:patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis;patients with relapsing-remitting multiple sclerosis and two or more relapses within the last two years;patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses.

European Union - English - EMA (European Medicines Agency)

biogen netherlands b.v.  - fampridine - multiple sclerosis - other nervous system drugs - fampyra is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (expanded disability status scale 4-7).

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - fingolimod hydrochloride  - multiple sclerosis - immunosuppressants - gilenya is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult patients and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4.4 and 5.1).orpatients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

European Union - English - EMA (European Medicines Agency)

sanofi belgium - alemtuzumab - multiple sclerosis - selective immunosuppressants - lemtrada is indicated for adult patients with relapsing-remitting multiple sclerosis (rrms) with active disease defined by clinical or imaging features.

European Union - English - EMA (European Medicines Agency)

biogen netherlands b.v. - dimethyl fumarate - multiple sclerosis - immunosuppressants - tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

European Union - English - EMA (European Medicines Agency)

biogen netherlands b.v. - peginterferon beta-1a - multiple sclerosis - immunostimulants, - treatment of relapsing remitting multiple sclerosis in adult patients.